ArticleFrontiers in immunology2026

Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer's disease.

Lizhen Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.